转变高胆固醇血症管理：聚焦 PCSK9 肽疫苗。
Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines.
机构信息
Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Liverpool Centre for Cardiovascular Science (LCCS), Liverpool, UK.
出版信息
Cell Rep Med. 2024 Sep 17;5(9):101726. doi: 10.1016/j.xcrm.2024.101726.
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al. and Zhang et al. in Cell Reports Medicine and Cell Reports, respectively, show the efficacy of peptide vaccines in eliciting an antibody response against PCSK9 and reducing plasma cholesterol levels.
摘要
脯氨酰肽链内切酶枯草溶菌素 9（PCSK9）是治疗血脂异常和动脉粥样硬化性心血管疾病（ASCVD）的靶点。方等人和张等人最近分别在《细胞报告医学》和《细胞报告》上发表的两项研究表明，肽疫苗在引发针对 PCSK9 的抗体反应和降低血浆胆固醇水平方面具有疗效。
相似文献
1
Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines.转变高胆固醇血症管理：聚焦 PCSK9 肽疫苗。
Cell Rep Med. 2024 Sep 17;5(9):101726. doi: 10.1016/j.xcrm.2024.101726.
2
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.抗前蛋白转化酶枯草溶菌素 9 型疫苗 AT04A 可降低 APOE*3Leiden.CETP 小鼠的总胆固醇、血管炎症和动脉粥样硬化。
Eur Heart J. 2017 Aug 21;38(32):2499-2507. doi: 10.1093/eurheartj/ehx260.
3
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.基于肽的抗PCSK9疫苗——一种长期管理低密度脂蛋白胆固醇（LDLc）的方法。
PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014.
4
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.通过针对9型前蛋白转化酶枯草杆菌蛋白酶/kexin进行免疫接种来降低低密度脂蛋白的疫苗策略。
Curr Opin Lipidol. 2016 Aug;27(4):345-50. doi: 10.1097/MOL.0000000000000312.
5
A Therapeutic Peptide Vaccine Against PCSK9.针对前蛋白转化酶枯草溶菌素 9（PCSK9）的治疗性肽疫苗。
Sci Rep. 2017 Oct 2;7(1):12534. doi: 10.1038/s41598-017-13069-w.
6
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
7
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.针对前蛋白转化酶枯草溶菌素 9 的新型靶向策略：超越单克隆抗体。
Cardiovasc Res. 2019 Mar 1;115(3):510-518. doi: 10.1093/cvr/cvz003.
8
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.前蛋白转化酶枯草溶菌素9单克隆抗体在他汀类药物无反应的高胆固醇血症和血脂异常患者中的治疗效果：一项系统评价和荟萃分析。
Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30.
9
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.前蛋白转化酶枯草溶菌素/克新9型在肾病综合征相关高胆固醇血症中的作用
Circulation. 2016 Jul 5;134(1):61-72. doi: 10.1161/CIRCULATIONAHA.115.020912.
10
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.针对枯草溶菌素转化酶 9 治疗血脂异常和动脉粥样硬化。
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
引用本文的文献
1
A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis.一种双靶向生物脂质体纳米药物可修复内皮细胞功能障碍并恢复巨噬细胞胆固醇流动稳态，以治疗早期动脉粥样硬化。
J Nanobiotechnology. 2025 May 20;23(1):365. doi: 10.1186/s12951-025-03436-5.
2
Oral PCSK9 Inhibitors: Will They Work?口服前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：它们会起作用吗？
Curr Atheroscler Rep. 2025 Apr 30;27(1):53. doi: 10.1007/s11883-025-01299-7.
本文引用的文献
1
Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.开发一种针对 PCSK9 的纳米疫苗，以有效降低高胆固醇血症。
Cell Rep Med. 2024 Jun 18;5(6):101614. doi: 10.1016/j.xcrm.2024.101614.
2
Cholesterol reduction by immunization with a PCSK9 mimic.通过免疫接种 PCSK9 模拟物降低胆固醇。
Cell Rep. 2024 Jun 25;43(6):114285. doi: 10.1016/j.celrep.2024.114285. Epub 2024 May 30.
3
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys.VXX-401，一种新型抗 PCSK9 疫苗，可降低食蟹猴的 LDL-C。
J Lipid Res. 2024 Feb;65(2):100497. doi: 10.1016/j.jlr.2024.100497. Epub 2024 Jan 10.
4
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?我们是否需要以及为什么需要研发一种抗动脉粥样硬化疫苗？我们能在近期内有所期待吗？
Curr Atheroscler Rep. 2024 Mar;26(3):59-71. doi: 10.1007/s11883-023-01186-z. Epub 2024 Jan 2.
5
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines.一种展示全长前蛋白转化酶枯草溶菌素9（PCSK9）的基于嵌合病毒样颗粒（cVLP）的疫苗，比类似的基于肽的cVLP疫苗能更有效地降低血浆中的PCSK9水平。
Vaccines (Basel). 2022 Dec 20;11(1):2. doi: 10.3390/vaccines11010002.
6
The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice.PCSK9 肽疫苗在小鼠中的免疫原性。
Curr Med Chem. 2023;30(26):3024-3031. doi: 10.2174/0929867329666220930114429.
7
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis.使用纳米脂质体进行前蛋白转化酶枯草溶菌素9免疫：对高胆固醇血症和动脉粥样硬化的预防效果
Arch Med Sci. 2021 Mar 18;17(5):1365-1377. doi: 10.5114/aoms/133885. eCollection 2021.
8
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.一项评估靶向 PCSK9 的免疫治疗药物的安全性、耐受性、免疫原性和降低低密度脂蛋白胆固醇活性的 I 期研究。
Eur J Clin Pharmacol. 2021 Oct;77(10):1473-1484. doi: 10.1007/s00228-021-03149-2. Epub 2021 May 10.
9
PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice.PCSK9Qβ-003 疫苗可减轻载脂蛋白 E 缺陷小鼠的动脉粥样硬化。
Cardiovasc Drugs Ther. 2021 Feb;35(1):141-151. doi: 10.1007/s10557-020-07041-6. Epub 2020 Jul 28.
10
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.利用基于纳米脂质体的疫苗传递系统长效生成抗 PCSK9 抗体。
Atherosclerosis. 2019 Apr;283:69-78. doi: 10.1016/j.atherosclerosis.2019.02.001. Epub 2019 Feb 14.
Zotero 插件